The Science and Technology Committee today agrees with, and commends, the scientific vision for the new UK Centre for Medical Research and Innovation, but expresses reservations about the project's location. It says the case for the centre's central London location near St Pancras station was not overwhelming and it could have been sited elsewhere. The advantages of co-location with universities and hospitals and access to good transport links, which the Committee accepts play a fundamental role in the centre's vision, come at a price: extra construction costs; a site incapable of expansion; and the concentration of medical sciences in the 'golden triangle' in the south of England. On the issue of funding, the Committee's concerns about the project's costs were assuaged by evidence from the Government that the taxpayer will not be liable to any further costs should the project overrun. On the management structure, the committee was told that an experienced team with a proven track record were now taking charge. The Committee is sympathetic to the local community's concerns about the project, and recognises attempts made by the centre's management to engage with the local community, but says it is saddened that efforts have not been as successful as they might have been. One way some benefit could accrue back to the local community is to ensure that the land released from the National Temperance Hospital site (the original site intended for the UKCMRI) is used for housing, including social housing.

This report, from the Innovation, Universities & Skills Committee, examines the establishment of the UK Centre for Medical Research and Innovation, to be located in central London, next to the British Library. This new body was created by the Medical Research Council (MRC), Cancer Research UK, the Wellcome Trust and University College London (UCL) and is to act as a centre for medical research bringing together the various science teams from these institutions. The establishment of UKCMRI though is both an exciting and risky venture, involving an estimated cost of £500 million, including nearly £300m of public funds through the Medical Research Council. The Committee has raised concerns about the financing of the project. At present, the Medical Research Council is to give £260m; Cancer Research UK, £150m; the Wellcome Trust, £100m and UCL, £46m. These figures are all estimates, and the Committee believes that the MRC need to establish an accurate breakdown of the costs involved in the project. Further, the Treasury's appropriation of £92m of the MRC's savings, has necessitated the MRC to apply for funding from The Large Facilities Capital Fund, and casts doubt over the MRC's ability to finance the project. Secondly, the Committee is concerned about the timetable and project management of the scheme, given the requirement of the MRC to apply for additional funding. Timetable challenges could be further acerbated by the construction and project management skills in demand for the 2012 Olympics. Also no planning permission had been gained from the local authority, Camden Borough Council, to use the site for a medical research centre. Finally the Committee is concerned about the science vision for the centre and that there is clear mission for the new institute, along with proper communication with staff over the direction of research programmes and facilities. The Committee expects to receive quarterly updates on the project's development.

In the realm of health care, privacy protections are needed to preserve patients' dignity and prevent possible harms. Ten years ago, to address these concerns as well as set guidelines for ethical health research, Congress called for a set of federal standards now known as the HIPAA Privacy Rule. In its 2009 report, Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research, the Institute of Medicine's Committee on Health Research and the Privacy of Health Information concludes that the HIPAA Privacy Rule does not protect privacy as well as it should, and that it impedes important health research.

This book brings together a collection of empirical case studies featuring a wide spectrum of medical innovation. While there is no unique pathway to successful medical innovation, recurring and distinctive features can be observed across different areas of clinical practice. This book examines why medical practice develops so unevenly across and within areas of disease, and how this relates to the underlying conditions of innovation across areas of practice. The contributions contained in this volume adopt a dynamic perspective on medical innovation based on the notion that scientific understanding, technology and clinical practice co-evolve along the co-ordinated search for solutions to medical problems. The chapters follow an historical approach to emphasise that the advancement of medical know-how is a contested, nuanced process, and that it involves a variety of knowledge bases whose evolutionary paths are rooted in the contexts in which they emerge. This book will be of interest to researchers and practitioners concerned with medical innovation, management studies and the economics of innovation. Chapter 5 of this book is freely available as a downloadable Open Access PDF at http://www.taylorfrancis.com under a Creative Commons Attribution-Non Commercial-No Derivatives (CC-BY-NC-ND) 3.0 license.

The very rapid pace of advances in biomedical research promises us a wide range of new drugs, medical devices, and clinical procedures. The extent to which these discoveries will benefit the public, however, depends in large part on the methods we choose for developing and testing them. Modern Methods of Clinical Investigation focuses on strategies for clinical evaluation and their role in uncovering the actual benefits and risks of medical innovation. Essays explore differences in our current systems for evaluating drugs, medical devices, and clinical procedures; health insurance databases as a tool for assessing treatment outcomes; the role of the medical profession, the Food and Drug Administration, and industry in stimulating the use of evaluative methods; and more. This book will be of special interest to policymakers, regulators, executives in the medical industry, clinical researchers, and physicians.

Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.

This guide helps officials use perception surveys for evaluating and communicating progress in regulatory reform. It explains the challenges involved in the design and use of business and citizen perception surveys – and ways to overcome them.